poisar

Stocks · News reference

DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides

Fiscal.ai

DataMEDS AI, Inc. reported the first commercial sale of compounded peptides by its Corexa Pharmacy unit, following compliance with recent HHS Enforcement Discretion Policy guidelines.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    DataMEDS AI, Inc. Reports Third Quarter 2026 Financial Results

    DataMEDS AI, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net operating profit of $10.535 million compared to a net operating loss of $34.318 million in the same period last year.